OneSource Pharma Scores USFDA Nod, Eyes Global Expansion with Xbrane Investment!

OneSource Specialty Pharma Ltd. has achieved a major regulatory milestone and signaled global ambitions with two strategic developments. The company’s Bangalorebased BLD facility has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the USFDA, following a detailed inspection in November 2024. At the same time, OneSource is proposing to subscribe to shares of Swedenbased Xbrane Biopharma AB, aiming to strengthen its biologics portfolio and widen its global footprint.

 

Key Highlights:

Together, these developments signal OneSource’s transformation into a globally competitive CDMO player with a keen eye on innovation, regulation, and biotech opportunity.

 

Sources: OneSource Press Release, Angel One, Express Pharma.